αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Case presentation Here we report a case of refractory EOC in a patient who had relapsed after multiline chemotherapy. The patient received autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (αPD-1). The modified T...
Main Authors: | Hui Wang, Zhong Li, Yan Sun, Wei Mao, Min Yuan, Juemin Fang, Qing Xu, Na Ding, Xinling Guo, Zhiwei Zhang, Bailu Xie, Zhicai Lin, Fei Qin, Wenqi Chu, Huanlong Qin, Qijun Qian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/2/e001162.full |
Similar Items
-
Clinical Observation of Apatinib in Treatment of Refractory Advanced Breast Cancer
by: WANG Jing, et al.
Published: (2020-11-01) -
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
by: Sun D, et al.
Published: (2018-10-01) -
Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
by: Zhang H, et al.
Published: (2017-02-01) -
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
by: Chaoxu Yang, et al.
Published: (2018-09-01) -
The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
by: Sun F, et al.
Published: (2020-07-01)